Preview

Cancer Urology

Advanced search

Clinical case of patient with ovarian cancer: possibilities of surgical treatment

https://doi.org/10.17650/1726-9776-2015-11-4-96-101

Abstract

Ovarian cancer (OC) occupies the third place in the structure of gynecological malignancies and it’s still known for its high mortality rate. Therefore this disease remains one of the actual problems in modern oncology. The standard of care for patients with OC consists of primary surgery, followed by platinum-based chemotherapy in a case of the disease recurrence. These combined chemotherapy regimens allow to make significant improvement in survival rates in patients with OC. Surgery is another treatment option which can be applied in patients with recurrent OC including disease recurrence after prior chemotherapy. This method enables to make considerable improvement in survival for this certain group of patients.

We report a clinical case of young patient suffering from recurrent OC. The disease was initially diagnosed in 2001. After that the patient underwent several types of surgery and multiple courses of polychemotherapy. Detection of disease recurrence in 2013 required to conduct a very complicated surgical treatment. Currently this patient is under active follow-up with no signs of disease progression or disease recurrence. Application of enterocystoplasty technique (bladder augmentation using bowel segments) in reconstruction of the urinary tract in this particular case enabled to preserve the quality of patient’s life as well as to conduct radical surgery. In order to reduce artificial bladder activity, reduce/eliminate urinary incontinence and improve the quality of patient’s life botulinum toxin A was injected into the bladder wall. The effect of this injection was positive. To sum up, teamwork between the members of urology and oncology departments done in time allowed to provide complete urologic help which included examination with the use of modern highly technological equipment and treatment followed by methods of neurological rehabilitation. All these led to significant improvement of the quality of the patient’s life.

About the Authors

B. Ya. Alekseyev
Moscow Scientific Research Institute of Oncology named after P.A. Herzen - branch of a State Budget Institution “The National Medical Radiological Center” of the Ministry of Health of the Russian Federation; 3 2nd Botkinsky Pr., Moscow, 125284, Russia Scientific Research Institute of Urology and Interventional Radiology named after N.A. Lopatkin – branch of a State Budget Institution “The National Medical Radiological Center” of the Ministry of Health of the Russian Federation; 51 3rd Parkovaya St., Moscow, 105425, Russia
Russian Federation


L. О. Petrov
Moscow Scientific Research Institute of Oncology named after P.A. Herzen - branch of a State Budget Institution “The National Medical Radiological Center” of the Ministry of Health of the Russian Federation; 3 2nd Botkinsky Pr., Moscow, 125284, Russia
Russian Federation


А. А. Krashennikov
Moscow Scientific Research Institute of Oncology named after P.A. Herzen - branch of a State Budget Institution “The National Medical Radiological Center” of the Ministry of Health of the Russian Federation; 3 2nd Botkinsky Pr., Moscow, 125284, Russia
Russian Federation


V. V. Romikh
Scientific Research Institute of Urology and Interventional Radiology named after N.A. Lopatkin – branch of a State Budget Institution “The National Medical Radiological Center” of the Ministry of Health of the Russian Federation; 51 3rd Parkovaya St., Moscow, 105425, Russia
Russian Federation


A. D. Kaprin
Moscow Scientific Research Institute of Oncology named after P.A. Herzen - branch of a State Budget Institution “The National Medical Radiological Center” of the Ministry of Health of the Russian Federation; 3 2nd Botkinsky Pr., Moscow, 125284, Russia Scientific Research Institute of Urology and Interventional Radiology named after N.A. Lopatkin – branch of a State Budget Institution “The National Medical Radiological Center” of the Ministry of Health of the Russian Federation; 51 3rd Parkovaya St., Moscow, 105425, Russia
Russian Federation


References

1. Злокачественные новообразования в России в 2013 году (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. М., 2015. 250 с. [Malignant neoplasms in Russia in 2013 (morbidity and mortality rate). Ed. by A.D. Kaprin, V.V. Starinskiy, G.V. Petrova. Мoscow, 2015. 250 p. (In Russ.)].

2. Ledermann J.A., Raja F.A. Clinical trials and decision-making strategies for optimal treatment of relapsed ovarian cancer. Eur J Cancer. 2011. 14. S104–S115.

3. Parmar M.K., Ledermann J.A., Colombo N. et al. Paclitaxel plus platinum-based chemotherapy versus conventional platinumbased chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet 2003;14(9375):2099–106.

4. Pfisterer J., Vergote I., Du Bois A. et al. Combination therapy with gemcitabine and carboplatin in recurrent ovarian cancer. Int J Gynecol Cancer 2005;14(Suppl 1): 36–41.

5. Aghajanian C., Blank S.V., Goff B.A. et al. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol 2012;14(17):2039–45.

6. Bristow R.E., Puri I., Chi D.S. Cytoreductive surgery for recurrent ovarian cancer: a meta-analysis. Gynecol Oncol 2009;14(1):265–74.

7. Van de Laar R., Zusterzeel P.L., Van Gorp T. et al. Cytoreductive surgery followed by chemotherapy versus chemotherapy alone for recurrent platinum-sensitive epithelial ovarian cancer (SOCceR trial): a multicenter randomized controlled study. BMC Cancer 2014;14:22 (abstr).

8. Fotopoulou C., Zang R., Gultekin M. et al. Value of tertiary cytoreductive surgery in epithelial ovarian cancer: an international multicenter evaluation. Ann Surg Oncol 2013;20:1348–54.


Review

For citations:


Alekseyev B.Ya., Petrov L.О., Krashennikov А.А., Romikh V.V., Kaprin A.D. Clinical case of patient with ovarian cancer: possibilities of surgical treatment. Cancer Urology. 2015;11(4):96-101. (In Russ.) https://doi.org/10.17650/1726-9776-2015-11-4-96-101

Views: 894


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1726-9776 (Print)
ISSN 1996-1812 (Online)
X